TD Cowen Raises Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,030.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective increased by equities research analysts at TD Cowen from $1,020.00 to $1,030.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. TD Cowen’s price target indicates a potential upside of 15.64% from the stock’s current price.

Several other analysts have also weighed in on the company. BMO Capital Markets upped their price objective on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a report on Monday, February 5th. Sanford C. Bernstein initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 target price for the company. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $925.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, April 15th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. Finally, Morgan Stanley upped their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a report on Wednesday, March 13th. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $977.77.

Regeneron Pharmaceuticals Trading Down 1.7 %

Shares of Regeneron Pharmaceuticals stock opened at $890.68 on Wednesday. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10. The firm has a market cap of $97.76 billion, a price-to-earnings ratio of 25.63, a price-to-earnings-growth ratio of 2.61 and a beta of 0.11. The business has a fifty day simple moving average of $949.30 and a 200-day simple moving average of $893.27. Regeneron Pharmaceuticals has a fifty-two week low of $684.80 and a fifty-two week high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating the consensus estimate of $10.73 by $1.13. The business had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The company’s revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $10.96 earnings per share. On average, equities analysts forecast that Regeneron Pharmaceuticals will post 38.8 EPS for the current fiscal year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the transaction, the executive vice president now directly owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the transaction, the executive vice president now directly owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $954.22, for a total value of $95,422.00. Following the completion of the transaction, the director now directly owns 18,382 shares in the company, valued at $17,540,472.04. The disclosure for this sale can be found here. Insiders have sold a total of 11,022 shares of company stock valued at $10,552,991 in the last three months. Insiders own 8.83% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in REGN. IFP Advisors Inc increased its holdings in shares of Regeneron Pharmaceuticals by 9.7% during the 3rd quarter. IFP Advisors Inc now owns 442 shares of the biopharmaceutical company’s stock valued at $364,000 after acquiring an additional 39 shares during the last quarter. Global Retirement Partners LLC increased its holdings in shares of Regeneron Pharmaceuticals by 67.1% during the 3rd quarter. Global Retirement Partners LLC now owns 249 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 100 shares during the last quarter. Park Place Capital Corp increased its holdings in shares of Regeneron Pharmaceuticals by 18.8% during the 3rd quarter. Park Place Capital Corp now owns 95 shares of the biopharmaceutical company’s stock valued at $78,000 after acquiring an additional 15 shares during the last quarter. Private Trust Co. NA increased its holdings in shares of Regeneron Pharmaceuticals by 30.4% during the 3rd quarter. Private Trust Co. NA now owns 403 shares of the biopharmaceutical company’s stock valued at $332,000 after acquiring an additional 94 shares during the last quarter. Finally, CX Institutional boosted its stake in Regeneron Pharmaceuticals by 10.7% during the 3rd quarter. CX Institutional now owns 311 shares of the biopharmaceutical company’s stock valued at $256,000 after purchasing an additional 30 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.